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Abstract 
Introduction The aim of this study is to estimate efficacy and safety of mesh in surgery for 
uterine or vault prolapse. 
Methods Seventeen electronic databases were searched for relevant studies that 
published from 1980 onwards.   
Results Fifty-four studies involving 7054 women were included.  For sacrocolpopexy 
(average follow up 23 months), the risk of clinical recurrence ranged from 0% to 6%, 
persistent symptoms ranged from 3% to 31%, and mesh erosion from 0% to 12%.  For 
infracoccygeal sacropexy (average follow up 13 months), the risk of clinical recurrence 
ranged from 0% to 25%, persistent symptoms from 2% to 21%, and mesh erosion 0% to 21%. 
Limited evidence was available for sacrocolpoperineopexy and uterine suspension sling to 
draw reliable estimates.  
Conclusion Sacrocolpopexy was associated with a low risk of recurrence but with a 
relatively high risk of mesh erosion. Ranges of estimates for outcomes for other mesh 
techniques were wide.  
(Word limit set by journal: 150) 
 
Keywords efficacy, mesh, mesh erosion, NICE, pelvic organ prolapsed, safety, systematic 
review  
 
Brief summary  Sacrocolpopexy was associated with a low risk of recurrence but a 
higher risk of mesh erosion. Ranges of estimates for other mesh techniques were wide.  
(Word limit set by journal: 25) 
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Introduction 
Prolapse of the uterus or vaginal vault (middle compartment) affects a woman’s health by its 
local physical effects (pressure, bulging, heaviness or discomfort) or its effect on urinary, 
bowel or sexual function. Current treatment options for uterine or vault prolapse include 
pelvic floor muscle training,[1] use of pessaries (mechanical devices such as rings or 
shelves)[2] and surgery.[3]  
Prolapse surgery not involving mesh includes hysterectomy, cervical amputation, and 
uterine/vault attachment with sutures to the pelvic ligaments.  Surgical techniques using mesh 
include sacrocolpopexy, sacrocolpoperineopexy, infracoccygeal sacropexy (also known as 
Posterior IntraVaginal Slingplasty, IVS), and uterine suspension sling.   
In sacrocolpopexy, the vaginal vault is attached with a mesh bridge to the periosteum 
of the sacral promontory.  If this is carried out at the same time as hysterectomy, the aim of 
the sacrocolpopexy is prophylaxis to prevent future vault prolapse.  Sacrocolpoperineopexy is 
a variation of sacrocolpopexy where extra mesh is inserted between the posterior vaginal wall 
and the rectum down to the perineum.  Use of sacrocolpoperineopexy is contentious because 
the relatively large amount of mesh may increase risks of mesh erosion. In infracoccygeal 
sacropexy, the uterus or vault is suspended using a mesh tape with the aid of a trochar 
(tunnelling device) through each of the ischiorectal fossae.  The uterine suspension sling 
technique can only be used in women who wish to conserve their uterus, i.e. for uterine 
prolapse repair. In this procedure, the uterus is attached with mesh to pelvic ligaments or to 
the periosteum of the sacral promontory.   
Both the efficacy and safety of mesh in surgery for uterine or vault prolapse are 
uncertain.  This report presents the estimated efficacy and safety of mesh in surgery for 
uterine or vault prolapse. It is based on a review that was commissioned through the UK 
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National Institute for Health and Clinical Excellence (NICE) Interventional Procedures 
Programme.   An electronic version of the full report is available from the NICE website.[4] 
 
Methods 
Search strategy 
We searched electronic databases, conference proceedings and relevant websites, contacted 
11 manufacturers, and scrutinised bibliographies of retrieved papers to identify reports of 
published and ongoing studies on the efficacy and safety of mesh in surgery for uterine or 
vault prolapse repair.  Searches, designed to be highly sensitive and using both controlled 
vocabulary and free-text terms, were restricted to publications from 1980 onwards, to those 
published in the English language and, for conference proceedings, to randomised controlled 
trials published from 2005 onwards. Studies that reported only procedures without mesh were 
not identified separately.  Full details of the search strategies used are reproduced in the 
original report[4] or are available from the authors.   
The databases searched were: Medline (1980 – Nov Wk 2 2007), Medline In-Process 
(4th Jan 2008), EMBASE (1980 – 2008 Wk 1), Biosis (1985 – 3rd Jan 2008), Science Citation 
Index (1980 – 5th Jan 2008), Cochrane Controlled Trials Register (The Cochrane Library, 
Issue 4 2007), and ISI Conference Proceedings (1990 – 11th Feb 2008) as well as current 
research registers (National Research Register (Issue 2, 2007), Current Controlled Trials (Jan 
2008) and Clinical Trials (Jan 2008).  Additional databases searched for systematic reviews 
and other background information included the Cochrane Database of Systematic Reviews 
(The Cochrane Library, Issue 4, 2007), Database of Abstracts of Reviews of Effectiveness 
(Jan 2008) and the HTA Database (Jan 2008). Conference proceedings of major 
urogynaecological organisations (American Urogynecologic Society (2005-6), American 
Urological Association (2005-7), European Association of Urology (2005-7), European 
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Society of Gynecological Endoscopy (2005-6), International Continence Society (2005-7)  
and International Urogynecological Association (2005-7) were scrutinised. 
 
Inclusion and exclusion criteria 
One reviewer screened titles/abstracts.  Any uncertainties were discussed with a second 
reviewer and consensus was reached.  Full text copies of all reports deemed to be potentially 
relevant were obtained and assessed by the main reviewer for inclusion. 
 Full-text RCTs, RCTs published as conference abstracts from 2005 onwards, non-
randomised comparative studies, and case series using mesh were sought.  As the volume of 
literature for sacrocolpopexy was substantial, only case series with a sample size of at least 
100 women were included.  There was no sample size restriction placed on case series that 
reported other mesh techniques because the volume of literature for these techniques was 
very limited.   
Case series with a mean follow up of at least one year were included for both efficacy 
and safety.  Case series with a mean follow up of less than one year were included for safety 
outcomes only.  We considered one year to be a minimum adequate period of time in which to 
assess the efficacy of prolapse repair.   
The participants were women undergoing uterine or vault prolapse surgery.  Studies 
of women with cancer or with prolapse caused by congenital anomalies, inherited conditions, 
or creation of a neovagina were excluded.  Studies with women undergoing other 
concomitant operations, such as anterior or posterior vaginal wall prolapse repair or anti-
incontinence procedures were included providing the main indication for surgery was uterine 
or vault prolapse.   
We considered all surgical techniques for uterine or vault prolapse repair which 
involved the use of mesh.  There were no restrictions on the type of mesh used.  For RCTs 
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and non-randomised comparative studies, the comparators were any other surgical techniques 
with or without mesh.   
The primary outcomes for efficacy were patient-reported persistent prolapse 
symptoms and clinician-reported recurrence of prolapse at the original site measured with a 
validated quantitative tool, e.g. the Pelvic Organ Prolapse-Quantification (POP-Q) system or 
Baden-Walker system.  Secondary outcomes for efficacy included:  new (de novo) prolapse 
at other sites that were free of prolapse before surgery; the need for repeat surgery for 
prolapse (both recurrent at the same site and de novo); persistent urinary symptoms; 
persistent bowel symptoms; and persistent sexual symptoms. For urinary, bowel, and sexual 
symptoms, only women who reported these symptoms at baseline were counted.  If possible, 
only women who were sexually active were considered for sexual function outcomes.   
The primary outcome for safety was mesh erosion. Secondary outcomes included: 
blood loss; damage to surrounding organs during the operation; an operation for mesh erosion 
or removal; new urinary, bowel or sexual symptoms; and infection. For new urinary, bowel 
or sexual symptoms, only women who were free of these symptoms at baseline were 
considered for these outcomes.   
We also considered other serious and minor adverse effects not otherwise specified, 
operation time, and hospital stay.  Details on these outcomes are provided in the full report.[4]  
 
Data extraction and quality assessment 
Data extraction and methodological quality assessment of the RCTs were conducted by two 
reviewers (XJ, CG) independently. The main reviewer (XJ) extracted data and assessed the 
quality of the remaining studies (due to resource constraints imposed by the review timelines).  
Two separate quality assessment checklists were used according to study design.  Both 
checklists were developed by the Review Body for Interventional Procedures (ReBIP; Health 
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Services Research Units at the Universities of Aberdeen and Sheffield), an independent 
review body that carries out systematic reviews for NICE’s Interventional Procedures 
Programme. The checklists were adapted from several sources.[5-7] 
 
Data analysis 
Four techniques that use mesh were identified: sacrocolpopexy, sacrocolpoperineopexy, 
infracoccygeal sacropexy, and uterine suspension sling. Data analyses were conducted 
separately for each of the technique, and for each technique, data were presented separately 
for three subgroups of women according to the type of prolapse being repaired:  uterine 
prolapse; vault prolapse; and uterine and/or vault prolapse (where the data were not reported 
separately).   
Meta-analyses were conducted of full-text RCTs, RCTs available as conference 
abstracts, and non-randomised comparative studies (using Cochrane Collaboration Review 
Manager, RevMan 4.3 software).  These allowed the efficacy and safety of procedures using 
mesh versus procedures without mesh, and between different techniques that used mesh, to be 
compared directly.  All tests of significance were performed at the 5% level.  For each 
outcome, the median and the range of the event rates were calculated by study design (RCTs, 
non-randomised comparative studies, case series/registries).  This required each arm of an 
RCT or comparative study to be considered as a separate case series.   
 Pre-specified subgroup analyses were planned for different surgical approaches 
(vaginal; open abdominal; and laparoscopic), different mesh types (non-absorbable synthetic 
mesh; absorbable synthetic mesh; biological absorbable graft; and combined mesh containing 
both absorbable and non-absorbable material) and for women having primary versus 
secondary repairs.   
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Results 
Number and type and quality of included studies 
From the initial 853 publications identified by the search strategy, 54 studies (reported in 60 
publications) were included, of which 5 were full-text RCTs,[8-12] 3 were RCTs available as 
conference abstracts,[13-15] 17 were non-randomised comparative studies,[16-32] and 29 
were case series.[33-61] Seven manufacturers provided relevant studies, all of which had 
already been identified by our searches. The screening process is summarised in Figure 1.  
Appendix 1 to 4 show details of study design, methods, participants, and interventions for 
sacrocolpopexy, sacrocolpoperineopexy, infracoccygeal sacropexy, and uterine suspension 
sling. Two studies involving 238 women reported a mixture of above techniques but did not 
report them separately.[20,40] Details and results of these two studies are available in the full 
report.[4] Seven ongoing RCTs[62-67] (personal communication: A Griffiths, Johnson & 
Johnson, 2007), one ongoing registry,[68] and one ongoing case series[66]  were also 
identified.   
The included studies took place during the period 1991 – 2007 in 16 countries.  
Overall, 7054 women were treated in total, of whom 4456 were treated with sacrocolpopexy, 
282 with sacrocolpoperineopexy, 976 with infracoccygeal sacropexy, 159 with uterine 
suspension sling, 238 a mixture of the above mesh techniques, and 943 with no-mesh 
techniques.   
Across studies, the average age of the women was 61 years.  Women who were treated 
with uterine suspension sling (a technique allows uterus to be preserved for future pregnancy) 
were younger (average age 37 years) than those treated with other techniques (average age 
around 65 years).  Only six studies provided information on whether the procedures were 
primary or secondary, of which two presented data on primary surgery alone.   
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We assessed the methodological quality of the full-text studies only because the 
abstracts only provided limited information about quality.  The study quality of RCTs, non-
randomised comparative studies, and case series is summarised in Figure  S1, S2 and S3 
respectively (supplementary data). 
 
Sacrocolpopexy 
Thirty-two studies (4 full-text RCTs,[8-11] 1 RCT available as conference abstract,[13] 15 
non-randomised comparative studies,[16-19,21-26,28-32] and 12 case series with sample 
sizes over 100) involving a total of 4456 women provided data on sacrocolpopexy.  Two 
studies[13,19] reported on uterine prolapse (hysterectomy followed by sacrocolpopexy in the 
same procedure), seven studies reported vault prolapse (sacrocolpopexy 
alone),[9,11,21,26,29,42,47] two studies reported uterine and vault prolapse separately,[23,61] 
and 21 studies[8,10,16-18,22,24,25,28,30-32,35-39,46,51,57,59] reported data from women 
having uterine and/or vault prolapse together (Appendix 1).  Mesh types varied across studies.  
The median (range) of mean follow up across these 32 studies was 23 months (8 to 66 
months).  Table 1 shows, for each type of study, the medians and ranges of event rates across 
studies for primary outcomes for sacrocolpopexy. 
 
Efficacy 
One small RCT involving 89 women with vault prolapse compared sacrocolpopexy (mesh) 
with sacrospinous colpopexy (no mesh): differences in risk of persistent symptom (RR 0.70, 
95% CI 0.17 to 2.95) and risk of prolapse recurrence (RR 0.23, 95% CI 0.05 to 1.04) were 
not statistically significant.[11]   
The risks of recurrence across all study designs ranged from 0% to 6% in 14 studies 
involving 1054 women (median 1.2%, Table 1), while the risks for persistent prolapse 
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symptoms ranged from 3% to 31% in 9 studies involving 638 women (median 22%).  In 4 
studies involving 451 women, risks of needing a further operation for recurrent or de novo 
prolapse ranged from 0% to 14% (median 8%).  Estimates for other outcomes were based on 
single studies only.   
 
Safety 
The risk of mesh erosion ranged from 0% to 12% (median 5.4%, 27 studies, n=2922, Table 
1). Zero to 11% of women required an operation for mesh erosion (median 3.8%, 17 studies, 
n=2074).  In studies reporting mesh erosion, most studies used non-absorbable synthetic 
mesh (Table 2). The median mesh erosion rates across studies were 4.0% (range 0% to 12.0%, 
21 studies, n=1869) for non-absorbable synthetic mesh compared with 0% (range 0% to 0.8%, 
5 studies, n=229) for absorbable biological graft. No studies reported mesh erosion data for 
absorbable synthetic mesh and only one study reported mesh erosion for combined mesh 
(4.3%, 1/23). 
For other safety outcomes, the proportion of women who required a blood transfusion 
for sacrocolpopexy ranged from 0% to 17% (median 1.7%, 19 studies, n=2080).  The range 
for women suffering organ damage varied from 0% to 8% (median 2.1%, 15 studies, n=1723).  
New urinary symptoms in women who did not have these symptoms at baseline occurred in 
4% to 9% (median 6.8%, 4 studies, n=294).  The estimate for new bowel symptoms (1%, 
2/178) was based on a single study, and the estimate for new sexual symptoms (range 9% to 
15%, n=87) was based on two small studies.  The range for infection was wide, which 
reflected the variety of ways used to define it (0.8% to 68%, 17 studies, n=1391).   
Data were available for meta-analysis comparing blood transfusion, damage to 
surrounding organs, infection and new urinary symptoms between sacrocolpopexy (mesh) 
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and sacrospinous colpopexy (no mesh).  There was not enough evidence to demonstrate a 
difference in any of these outcomes between the operations.[4]   
 
Sacrocolpoperineopexy 
Two studies involving 442 women reported on sacrocolpoperineopexy.[31,58] (Appendix 2). 
Table 3 shows the event rates for primary outcomes for sacrocolpoperineopexy. Neither of the 
two studies gave details of uterine and vault prolapse separately. Risks of mesh erosion 
reported by these two studies were similar (8.5% in 118 women in 6 months and 8.3% in 169 
women in 14 months). 
 
Infracoccygeal sacropexy (posterior IVS) 
Fourteen studies (2 RCTs available as conference abstracts,[14,15] 1 non-randomised 
comparative study,[27] 2 case series with sample sizes ≥100, [45,60] and 9 case series with 
sample sizes <100[41,43,44,48,52-56]) involving 976 women provided data on 
infracoccygeal sacropexy. One study[27] reported uterine repair (uterus conserved), 
5[14,41,43,44,53] reported vault repair, onereported uterine and vault repairs separately[56], 
and 7[15,45,48,52,54,55,60] studies reported uterine and vault repairs together (Appendix 3).  
The median follow up across these 14 studies was 13 months (range 5 to 30 months).  The 
ranges of event rates for primary outcomes are shown in Table 4.  Meta-analysis was not 
possible because the comparative studies used different comparators.   
 
Efficacy 
The proportion of women with persistent prolapse symptoms ranged from 2% to 21% 
(median 8.8%, n=262, 3 studies) after infracoccygeal sacropexy, whereas the range for 
prolapsed recurrence was 0% to 25% (median 4.8%, 9 studies, n=402).  In 3 studies (n=288), 
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the re-operation rate varied from none to 30% (median 7.9%).  Estimates for other outcomes 
were based on single studies with few women.   
 
Safety 
The risks of mesh erosion ranged from 0% to 21% (median 6.7%, 11 studies, n=889), and 
0.3% to 17% of women needed an operation for mesh erosion (median 7.2%, 6 studies, 
n=678).  All studies reporting mesh erosion used non-absorbable synthetic mesh. The need 
for blood transfusion ranged from 0% to 2% (7 studies, n=383).  The risks of organ damage 
ranged from 0% to 2.7% (median 0%, 9 studies, n=684).  Little evidence was available for 
new urinary symptoms, bowel symptoms, and sexual symptoms in women who did not have 
these symptoms at baseline.  Infection ranged from 0% to 9% (8 studies, n=698).   
 
Uterine suspension sling 
Six studies[12,19,33,34,49,50] involving 239 women reported on uterine suspension sling 
operations.  One was a full-text RCT,[12] one was a non-randomised comparative study,[19] 
and four were case series[33,34,49,50] (Appendix 4).  All of the case series had a sample size 
of less than 100.  Five of the six studies reported sacrohysteropexy (uterus suspended to the 
sacrum with a mesh bridge) and the other[49] reported a different technique (suspending the 
uterus to the pectineal ligaments).  The median follow up across the six studies was 33 
months (12 to 95 months).  Meta-analysis was not possible because the comparative studies 
used different comparators.   
 
Efficacy, safety, operation time and hospital stay  
Table 5 shows the event rates for primary outcomes.  The range of persistent prolapse 
symptoms was wide (0% to 39%, median 3.3%, 3 studies, n=91).  The risks of recurrence 
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ranged from 0% to 8% (median 3.3%, 5 studies, n=136), while the risks of requiring a re-
operation for prolapse ranged from 0% to 22% (median 3.3%, 3 studies, n=107).  Little 
evidence was available for estimating other efficacy outcomes or any of the safety outcomes.   
 
Discussion 
Summary of the evidence 
The review indicated that although sacrocolpopexy is associated with an apparent risk of 
clinical recurrence ranging from 0% to 6% (at an average follow up of two years), the 
incidence of persistent prolapse symptoms (range 3% to 31%) and need for a further prolapse 
operation (range 2% to 25%) were relatively high.  There were risks from adverse effects 
such as mesh erosion (range 0% to 12%), which often required a further operation for mesh 
erosion (range 1% to 11%).  Non-absorbable mesh was associated with a higher risk of mesh 
erosion (median 4.0%, range 0% to 12.0%) compared with absorbable biological graft 
(median 0%, range 0% to 0.8%).  
Sacrocolpoperineopexy was associated with 8% of mesh erosion at an average follow 
up of one year. Little evidence was available for other outcomes.    
For infracoccygeal sacropexy, persistent symptoms ranged from 2% to 21% at an 
average follow up of one year, clinical recurrence varied from 0% to 25%, mesh erosion from 
0% to 21%, and operation for mesh erosion from 2% to 17%.   
For uterine suspension sling, the clinical recurrence rates ranged from 0% to 8% at an 
average follow up of three years, whereas persistent symptoms ranged from 0% to 39%. 
However, little evidence was available for safety outcomes.   
 
Assumptions, limitations, and uncertainties 
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We aimed to review separately data from women having uterine prolapse and vault prolapse, 
because the operations, and hence the efficacy and safety, might be different in these two 
populations.  However, the majority of the studies (32/54) reported data from women having 
uterine or vault repairs without separating the groups.  As there was limited evidence for 
uterine prolapse repair and for vault prolapse repair alone, we did review evidence from 
studies that reported a mixture of uterine and vault prolapse.   
  We did not separate data by surgical approach. We are aware that the laparoscopic 
approach is gaining in popularity. This could be applied in sacrocolpopexy, 
sacrocolpoperineopexy, or uterine suspension sling. A small proportion of the included 
studies reported that the operations were done laparoscopically and were all for 
sacrocolpopexy (7.5%, 336/4456).[25,26,29,32,46] 
It is important to determine whether safety and efficacy of mesh differ in women 
having primary versus recurrent prolapse repairs.  However, of the 54 included studies, only 
two case series[35,61] reported exclusively on women having primary repairs.  Another four 
studies[18,34,49,51] reported the case mix of primary and secondary operations but did not 
report outcome data separately for the two groups.  It is likely that the remaining 48 studies 
included women having both primary and secondary surgery but this was not reported.   
There was a very limited number of RCTs available (20%, 11/54) of which five were 
available only as conference abstracts. The number of RCTs in each subgroup (by two types 
of prolapse, and by four different surgical techniques) was even smaller (Appendices 1 to 4). 
Data were therefore too few to compare efficacy and safety between surgical techniques 
using mesh (each type) and no mesh and between different mesh techniques.   
We pragmatically considered one year as an adequate minimum period of time to 
assess the efficacy of middle compartment prolapse repair.  However, as the mean time to 
reoperation is 12 years[69] one year may be too short to judge success.  Therefore failure rates 
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at one year may not be representative of longer-term efficacy.  Prospective studies will require 
extended follow up to assess meaningful mesh failure rates.   
Nevertheless, the results were considered generalisable as the majority of studies 
recruited participants from a spectrum of routine practice, without restrictions for the severity 
of prolapse or other patient characteristics.   
 
Conclusions and implications 
In general, sacrocolpopexy was associated with a low risk of recurrence, but the risks of 
persistent prolapse symptoms, re-operation, and mesh erosion were relatively high.  The 
estimates for the efficacy and safety outcomes for infracoccygeal sacropexy were wide.  
There was only limited evidence for efficacy and safety for sacrocolpoperineopexy or uterine 
suspension sling.   
In consequence, in January 2009, NICE (UK) recommended that, for all but 
sacrocolpopexy for vaginal vault prolapse repair,[70] ‘special arrangements for clinical 
governance, consent and audit or research’ should be used.[71-74]  The implications are that 
the ‘clinical governance leads in their Trusts should be informed, and patients need to be 
explicitly counselled about the uncertainty regarding safety and efficacy.  Clear written 
information must be provided’.  NICE also recommend that clinicians should enter details 
about all patients undergoing the procedures on the British Society for Urogynaecology 
Database so that a UK-wide audit of current practice can be carried out.   
In addition, rigorous RCTs, with adequate power to detect clinically meaningful 
differences and long-term outcomes, are needed to determine the comparative efficacy of 
mesh techniques and their optimal place in the treatment of middle compartment prolapse.  
They should use validated patient-reported outcome measures, primarily to compare the 
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failure rates and safety profiles, between mesh and no-mesh techniques, between different 
types of mesh techniques, and between different types of mesh.   
 
(Word count: 3503). 
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Figure 1 Flow diagram for screening process. 
 
Potentially relevant reports identified 
and screened for retrieval (n=853) 
Reports retrieved for more detailed 
evaluation (n=281) 
Studies included (n=54, in 67 reports):  
5 full text RCTs,  
3 RCTs available as conference abstract, 
17 non-randomised comparative studies,  
29 case series  
Excluded reports (n=227): 
Case series reporting sacrocolpopexy but 
sample size < 100 (n=100), 
No mesh used (n=18), 
Data not presented separately for uterine or 
vault repair or for mesh techniques (n=14), 
No data reported (n=4), 
Other reasons, e.g. reviews (n=91) 
Excluded reports (n=572): not meeting 
inclusion criteria, e.g. no mesh was used 
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Table 1 Median and ranges of event rates for primary efficacy and safety outcomes for sacrocolpopexy 
 Uterine Vault Uterine and/or vault 
 No. study n/N, % Median (range) No. study n/N, % Median (range) No. study n/N, % Median (range) 
Patient reported persistent prolapse symptoms 
RCT 0   1 3/46 (6.5%) 6.5% 1 6/38 (16%) 16% 
RCT (abs.) 0   0   0   
Non-rand 0   1 13/60 (22%) 22% 2a 11/97 (11%) 14% (3.3-24) 
Case series 0   1 22/103 (21%) 21% 3 77/294 (26%) 26% (23-31) 
Total Median 2.2% (range 3-31), based on 9 studies (638 women) 
Clinician reported recurrent prolapse at original site 
RCT 0   2a 2/135 (1.5%) 2.2% (0-4.3) 1 0/52 (0%) 0% 
RCT (abs.) 1 0/23 (0%) 0% 0   0   
Non-rand 1 0/39 (0%) 0% 2a 2/105 (1.9%) 2.2% (0-4.4) 2 4/140 (2.9%) 3.1% (1.3-5.0) 
Case series 0   1 4/66 (6.1%) 6.1% 4 8/494 (1.6%) 1.8% (0-3.1) 
Total Median 1.2% (range 0-6.1), based on 14 studies (1054 women) 
Mesh erosion 
RCT 0   2a 3/147 (2.0%) 2.1% (2.0-2.1) 0   
RCT (abs.) 1 1/23 (4.3%) 4.3% 0   0   
Non-rand 2a 12/143 (8.4%) 8.2% (7.7-8.7) 2b 7/162 (4.3%) 5.7% (2.6-8.9) 8c 22/577 (3.8%) 2.4% (0-12) 
Case series 1 7/101 (6.9%) 6.9% 4 35/660 (5.3%) 6.5% (0-8.7) 7 31/1109 (2.8%) 2.4% (1.0-6.5) 
Total Median 5.4% (range 0-12), based on 27 studies (2922 women) 
 
a,b.c Results from the two arms of one/two/four studies were combined
 32 
Table 2 Median and ranges of mesh erosion rates for sacrocolpopexya,b 
 No. study n/N (%) Median (range) 
Non-absorbable synthetic mesh 
Uterine 3 19/280 (6.8%) 6.9% (4.0-8.7) 
Vault 7 42/806 (5.2%) 4.7% (0-8.9) 
Uterine and/or vault 11 26/783 (3.3%) 5.0% (0-12.0) 
Total  21 87/1869 (4.7%) 4.0% (0-12) 
Absorbable synthetic mesh (no study reported data on this) 
Absorbable biological graft 
Uterine 0   
Vault 1 0/46 (0%) 0% 
Uterine and/or vault 4 1/183 (0.5%) 0% (0-0.8%) 
Total  5 1/229 (0.4%) 0% (0-0.8) 
Combined (contain both non-absorbable and absorbable material) 
Uterine 1 1/23 (4.3%) 4.3% 
Vault 0   
Uterine and/or vault 0   
Total  1 1/23 (4.3%) 4.3% 
 
aFour studies reported two different types of mesh separately. 
bFive studies (5/27, 18.5 %) that reported data on mesh erosion were not included in this table because they either did not report type of mesh used or used a 
mixture of different types but not reported them separately. 
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Table 3 Median and ranges of event rates for primary efficacy and safety outcomes for sacrocolpoperineopexy 
 Sacrocolpoperineopexy 
(not reported separately by uterine and vault) 
 No. study n/N, % Median (range) 
Patient reported persistent prolapse symptoms 
RCT 0   
RCT (abstract) 0   
Non-randomised comparative studies 0   
Case series 1 2/169 (1.2%) 1.2% 
Total Median 1.2%, based on 1 study (169 women) 
Clinician reported recurrent prolapse at original site 
RCT 0   
RCT (abstract) 0   
Non-randomised comparative studies 0   
Case series 1 1/169 (0.6%) 0.6% 
Total Median 0.6%, based on 1 study (169 women) 
Mesh erosion 
RCT 0   
RCT (abstract) 0   
Non-randomised comparative studies 1 10/118 (8.5%) 8.5% 
Case series 1 14/169 (8.3%) 8.3% 
Total Median 8.4% (range 8.3-8.5), based on 2 studies (287 women) 
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Table 4 Median and ranges of event rates for primary efficacy and safety outcomes for infracoccygeal sacropexy  
 Uterine Vault Uterine and/or vault 
 No. study n/N, % Median (range) No. study n/N, % Median (range) No. study n/N, % Median (range) 
Patient reported persistent prolapse symptoms 
RCT 0   0   0   
RCT (abs.) 0   0   0   
Non-rand 0   0   0   
Case series 0   1 8/91 (8.8%) 8.8% 2 28/171 (16%) 12% (2.3-21) 
Total Median 8.8% (range 2-21), based on 3 studies (262 women) 
Clinician reported recurrent prolapse at original site 
RCT 0   0   0   
RCT (abs.) 0   0   1 1/21 (4.8%) 4.8% 
Non-rand 1a 1/79 (1.3%) 1.3% 0   0   
Case series 1 1/10 (10%) 10% 2 4/60 (6.7%) 5.0% (0-10) 4 17/232 (7.3%) 6.5% (0-25) 
Total Median 4.8% (range 0-25), based on 9 studies (402 women) 
Mesh erosion 
RCT 0   0   0   
RCT (abs.) 0   1 2/30 (6.7%) 6.7% 1 0/21 (0%) 0% 
Non-rand 1a 10/79 (13%) 13% 0   0   
Case series 0   4 22/235 (9.4%) 6.6% (5.3-21%) 4 33/524 (6.3%) 5.6% (1.5-17) 
Total Median 6.7% (range 0-21), based on 11 studies (889 women) 
 
a Results from the two arms of one study were combined 
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Table 5 Median and ranges of event rates for primary efficacy and safety outcomes for uterine suspension sling  
 Uterine suspension sling 
(for uterine prolapsed only) 
 No. study n/N, % Median (range) 
Patient reported persistent prolapse symptoms 
RCT 1 16/41 (39%) 39% 
RCT (abstract) 0   
Non-randomised comparative studies 0   
Case series 2 1/50 (2.0%) 1.6% (0-3.3) 
Total Median 3.3% (range 0-39), based on 3 studies (91 women) 
Clinician reported recurrent prolapse at original site 
RCT 1 2/38 (5.3%) 5.3% 
RCT (abstract) 0   
Non-randomised comparative studies 1 0/36 (0%) 0% 
Case series 3 2/62 (3.2%) 3.3% (0-7.7) 
Total Median 3.3% (range 0-7.7), based on 5 studies (136 women) 
Mesh erosion 
RCT 0   
RCT (abstract) 0   
Non-randomised comparative studies 1 0/36 (0%) 0 
Case series 1 1/30 (3.3%) 3.3% 
Total Median 1.7% (range 0-3.3), based on 2 studies (66 women) 
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Appendix 1  Sacrocolpopexy: summary of patient characteristics and surgical procedures 
 
ID N Age, y Uterine/ 
vault 
Primary/ 
secondary 
Intervention route Technique  Mesh/graft, trade name Concomitant 
procedure 
Follow up, mean Outcomes  
UTERINE            
RCT (abs.)           
Braun 2007[13] A, 23 
B, 24 
A, 57 
B, 56 
A, 23/0 
B, 24/0 
NR A, abdominal  
B, vaginal 
A, hysterectomy + sacrocolpopexy; 
B, hysterectomy + anteroposterior 
colporrhaphy + Mayo McCall stitch 
A, combined mesh, polyglactin 
and prolene 1 :1, Vypro 
B, no mesh 
NR 33m (20-41) Efficacy 
Safety  
Non-randomised comparative studies 
Costantini 
2005[19] 
A, 36 
B, 39 
A, 61 (12) 
B, 62 (8) 
A, 36/0 
B, 39/0 
NR A, abdominal 
B, abdominal 
A, sacrohysteropexy 
B, hysterectomy + sacrocolpopexy 
A, polypropylene, Marlex 
(Amid type I) 
B, same as A 
Anti-incontinence: 
A, 28/36; B, 30/39 
Hysterectomy: 
A, 0/36; B, 39/39 
 
51m (12-115) Efficacy 
Safety  
Griffis 2006[23] A, 60 
B, 28 
NR A, 60/0 
B, 28/0 
NR A, abdominal 
B, abdominal 
A, total hysterectomy + sacrocolpopexy 
B, supracervical hysterectomy + 
sacrocolpopexy 
A, polypropylene, Prolene soft, 
Prolene (Amid type I), or 
Atrium (NR Amid type); 
polyethylene tetraphalate, 
Mersilene (Amid type III) 
B, same as A 
NR 13m (12-15) Safety  
Case series           
Wu 2006[61] 101 64 (12) 101/0 101/0 Abdominal (open) Hysterectomy + sacrocolpopexy polyethylene tetraphalate, 
Mersilene (Amid type III); 
polypropylene (NR trade name); 
or Gore-Tex (Amid type II) 
NR 15m (0.2-120) Safety  
VAULT           
RCT           
Culligan 2005[9] A, 54 
B, 46 
A, 60 (10) 
B, 58 (11) 
A, 0/54 
B, 0/46 
NR A, abdominal (open) 
B, abdominal (open) 
A, sacrocolpopexy 
B, sacrocolpopexy 
A, polypropylene, Trelex 
B, cadaveric fascia lata, 
Tutoplast 
NR 1y Efficacy 
Safety 
Maher 2004[11] A, 47 
B, 48 
A, 63 (39-84) 
B, 63 (35-88) 
A, 0/47 
B, 0/48 
NR A, abdominal 
B, vaginal 
A, sacrocolpopexy 
B, unilateral vaginal sacrospinous 
colpopexy 
A, polypropylene, Prolene 
(Amid type I) 
B, no mesh 
NR 24m (6-60) Efficacy 
Safety 
 
Non-randomised comparative studies 
Govier 2005[21] A, 24 
B, 21 
A+B, 67 (51-
86) 
A, 0/24 
B, 0/21 
NR A, abdominal (open or 
laparoscopic) 
B, abdominal (open or 
laparoscopic) 
 
A, sacrocolpopexy 
B, sacrocolpopexy 
A, polypropylene, Prolene  
B, silicone-covered 
polyethylene mesh, American 
Medical Systems 
A+B, 20/45 A, 12m (1-38) 
B, 23m (16-41) 
Efficacy 
Safety 
 
Marcickiewicz 
2007[26] 
A, 60 
B, 51 
A, 58 (30-83) 
B, 66 (43-88) 
A, 0/60 
B, 0/51 
NR A, abdominal 
(laparoscopic) 
B, vaginal 
 
A, sacrocolpopexy 
B, sacrospinous colpopexy 
A, polypropylene, Prolene 
B, no mesh 
A, 6/60; B, 8/51 A, 34m (13-60) 
B, 38m (7-108) 
 
Efficacy 
Safety  
Paraiso 2005[29] A, 56 
B, 61 
A, 62 (39-85) 
B, 61 (35-81) 
A, 0/56 
B, 0/61 
NR A, abdominal 
(laparoscopic) 
B, abdominal (open) 
A, sacrocolpopexy 
B, sacrocolpopexy 
A, cadaveric fascia lata, 
Tutoplast, or polypropylene, 
Prolene 
B, save as above 
A, 24/56; B, 38/61 
  
A, 14m (1-46) 
B, 16m (1-73) 
Safety 
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ID N Age, y Uterine/ 
vault 
Primary/ 
secondary 
Intervention route Technique  Mesh/graft, trade name Concomitant 
procedure 
Follow up, mean Outcomes  
Case series           
Fedorkow 
1993[42] 
 
149 58 (11) 0/149 NR Abdominal  Sacrocolpopexy  
 
Polypropylene, Prolene (Amid 
type I) 
NR NR Safety 
Griffis 2006[23] 196 NR 0/196 NR Abdominal  Sacrocolpopexy  Polypropylene, Prolene-Soft, 
Prolene (Amid type I), or 
Atrium (NR Amid type); 
polyethylene tetraphalate, 
Mersilene (Amid type III). 
 
NR 13m Safety  
Higgs 2005a[47] 103 58 (10) 0/103 NR Abdominal 
(laparoscopic) 
Sacrocolpopexy  Polypropylene, Prolene (Amid 
type I) 
 
39/103 66m (37-124) Efficacy 
Safety  
Wu 2006[61] 212 66 (11) 0/212 212/0 Abdominal (open) Sacrocolpopexy  Polyethylene  tetraphalate, 
Mersilene (Amid type III); 
polypropylene (NR trade 
name); or Gore-Tex 
NR 15m (0.3-121) Safety  
UTERINE AND/OR VAULT         
RCT           
Benson 1996[8] A, 40 
B, 48 
A, 66 (10) 
B, 64 (9) 
NR NR A, abdominal 
B, vaginal 
A, sacrocolpopexy  
B, bilateral sacrospinous ligament vault 
suspension 
 
A, NR 
B, no mesh 
Anti-incontinence:  
A, 14/40; B, 20/48 
Hysterectomy:  
A, 20/40; B, 24/48 
 
2.5y (1-5.5) Efficacy  
Safety  
Lo 1998[10] A, 52 
B, 66 
A, 63 (9) 
B, 60 (10) 
NR NR A, abdominal (open) 
B, vaginal 
A, sacrocolpopexy 
B, sacrospinous ligament suspension 
A, polyethylene tetraphalate, 
Mersilene (Amid type III) 
B, no mesh 
Anti-incontinence: 
A, 0/52; B, 0/66 
Hysterectomy: 
A, 33/52; B, 20/66 
2.1y (1-5.2) Efficacy 
Safety 
 
Non-randomised comparative studies 
Altman 2005[16] A, 25 
B, 27 
A, 66 (54-83) 
B, 69 (55-84) 
NR NR A, abdominal 
B, abdominal 
A, sacrocolpopexy 
B, sacrocolpopexy 
A, 12 polypropylene, 13 
polytetrafluoroethylene (NR 
trade name) 
B, porcine dermis, Pelvicol 
 
Hysterectomy: 
A, 2/25; B, 5/27 
Efficacy 
A, 7.4m; B, 7.1m 
Safety 
A, 4.3y; B, 2.5y 
 
Safety  
Bai 2006[17] A, 20 
B, 54 
NR NR NR A, abdominal 
B, abdominal 
A, sacrocolpopexy 
B, high uterosacral colpopexy 
A, polyethylene tetraphalate, 
Mersilene (Amid type III) 
B, no mesh 
 
Performed if needed 
but NR numbers. 
1y Safety  
Begley 2005[18] A, 24 
B, 33 
C, 21 
D, 14 
A, 69 (49-86)  
B, 66 (37-84) 
C, 66 (40-85) 
D, 63 (25-83) 
NR A+B, 85/7 A, abdominal (19 
open, 5 laparoscopic) 
B, abdominal (open) 
C, abdominal (18 
open, 3 laparoscopic) 
D, abdominal (open) 
A, sacrocolpopexy 
B, sacrocolpopexy 
C, sacrocolpopexy 
D, sacrocolpopexy 
A, polypropylene, Marlex or 
Prolene (Amid type I) 
B, polypropylene, Gore-Tex 
(Amid type II) 
C, silicon-covered polyester, 
American Medical Systems  
D, 1 autologous and 13 
cadaveric fascia lata, Tutoplast 
Anti-incontinence: 
A, 9/24; B, 14/33; 
C, 9/21; D, 5/14 
Hysterectomy: 
A, 1/24; B, 8/33; C, 
3/21; D, 7/14 
A, 10m 
B, 29m 
C, 16m 
D, 19m 
Efficacy 
Safety 
 
 38 
ID N Age, y Uterine/ 
vault 
Primary/ 
secondary 
Intervention route Technique  Mesh/graft, trade name Concomitant 
procedure 
Follow up, mean Outcomes  
 
Gregory 
2005[22] 
A, 49 
B, 33 
NR  NR NR A, abdominal (open) 
B, abdominal (open) 
A, sacrocolpopexy 
B, sacrocolpopexy 
A, polypropylene, Marlex 
(Amid type I); polyethylene 
tetraphalate, Mersilene (Amid 
type II) 
B, fascia lata, Community 
Tissue Services  
 
Performed but NR 
numbers 
A, 26 (10-48) 
B, 21 (11-34) 
Efficacy 
Safety  
Hardiman 
1996[24] 
A, 80 
B, 125 
A, 61  
B, 64 
NR NR A, abdominal 
B, vaginal 
A, sacrocolpopexy 
B, sacrospinous vault suspension 
A, polypropylene, Marlex 
(Amid type I) 
B, no mesh 
 
Anti-incontinence: 
A, 76/80; B, 45/125 
Hysterectomy: 
A, 18/80; B, 45/125 
 
A, 3.9y 
B, 2.2y 
A+B, 6m-5y 
Efficacy 
Safety  
Hsiao 2007[25] A, 25 
B, 22 
A, 66 
B, 71 
A, 2/23 
B, 3/19 
NR A, abdominal 
(laparoscopic) 
B, abdominal (open) 
A, sacrocolpopexy 
B, sacrocolpopexy 
A, 19 polypropylene, Prolene; 
3 silicone mesh 
B, 2 fascia lata; 13 
polypropylene, Prolene; 5 
silicon mesh; 2 polypropylene, 
Gore-Tex 
 
Anti-incontinence: 
A, 9/25; B, 10/22 
Hysterectomy:  
NR 
A, 6m 
B, 10m 
Safety  
Ng 2004[28] 
 
 
 
 
 
A, 113 
B, 64 
A, 60 
B, 63 
A, 78/35 
B, 37/27 
NR A, abdominal (open) 
B, vaginal 
A, sacrocolpopexy 
B, sacrospinous ligament fixation 
A, polytetrafluoroethylene, 
Gore-Tex (Amid type II) 
B, no mesh 
Anti-incontinence: 
A, 28/113; B, 12/64 
Hysterectomy:  
A, 78/113; B, 38/64 
 
A, 18m (1-48) 
B, 13m (1-29) 
Efficacy 
Safety  
Sze 1999[30] A, 56 
B, 61 
A, 57 (34-74) 
B, 64 (43-76) 
A, 19/35 
B, 7/40 
NR A, abdominal (open) 
B, vaginal 
A, sacrocolpopexy 
B, sacrospinous ligament fixation 
A, NR 
B, no mesh 
Anti-incontinence: 
A, 56/56; B, 61/61 
Hysterectomy: 
A, 7/56; B, 19/61 
 
A, 23m (4-51) 
B, 24m (7-72) 
Safety 
Visco 2001[31] A, 155 
B, 88 
C, 25 
D, 5 
A+B+C+D, 61 
(31-84) 
NR NR A, abdominal 
B, abdominal 
C, vaginal+ abdominal 
D, vaginal+ abdominal 
 
A, sacrocolpopexy 
B, sacrocolpoperineopexy  
C, sacrocolpoperineopexy 
D, sacrocolpoperineopexy with mesh 
placed to vaginal field 
 
A, polyethylene tetraphalate, 
Mersilene (Amid type III) or 
Gore-Tex (Amid type II) 
B, C, D, same as above 
Anti-incontinence: 
NR 
Hysterectomy: 
A+B+C+D: 45/273 
A, 7m (1-87) 
B, 5 (1-45) 
C, 6m (1-28) 
D, 7m (2-11) 
 
Young 2004[32] 
(prospective 
registry) 
A, 92 
B, 187 
C, 70 
A, 61 (28-84) 
B, 37-87 
C, 64 (34-84) 
NR NR A, abdominal 
(laparoscopic) 
B, vaginal 
C, vaginal 
A, sacrocolpopexy 
B, sacrospinous fixation 
C, high uterosacral suspension 
A, a mixture of biological 
grafts and non-absorbable 
synthetic mesh 
B, no mesh 
C, no mesh 
Anti-incontinence: 
A, 44/92; B, 28/187; 
C, 8/70 
Hysterectomy: 
A, 6/92; B, 63/187; C, 
17/70 
NR, a safety 
registry in a year 
(Oct. 1998-Oct. 
1999) 
Safety  
Case series           
Bensinger 
2005[35] 
121 53 (10) 86/35 121/0 Abdominal  Sacrocolpopexy  Polypropylene (NR trade 
name) 
 
Anti-incontinence: 
82/121 
Hysterectomy: NR 
13m (0.3-63) Safety  
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ID N Age, y Uterine/ 
vault 
Primary/ 
secondary 
Intervention route Technique  Mesh/graft, trade name Concomitant 
procedure 
Follow up, mean Outcomes  
 
Brizzolara 
2003[37] 
124 65 (9) 60/64 NR Abdominal  Sacrocolpopexy   Polypropylene, Prolene, or 
allograft (NR trade name) 
Anti-incontinence: 
92/124 
Hysterectomy: NR 
 
36m (0-74) Efficacy  
Safety  
Bradley 2007[36] 305 NR NR NR Abdominal (open) Sacrocolpopexy  Non-absorbable synthetic, 
xenograft, autologous or 
cadaveric fascia lata  
Anti-incontinence: 
148/305 
1y Efficacy 
Safety  
Culligan 
2002[38] 
245 61 (32-83) NR NR Abdominal  Sacrocolpopexy  Synthetic mesh (NR trade 
name) 
Anti-incontinence: 
171/245 
Hysterectomy: 11/245 
Objective 
failure: >=4y; 
subjective 
failure: 3.3y (0.8-
6.9) 
Efficacy 
Safety  
De Vries 
1995[39] 
101 59 (37-82) 15/83 NR Abdominal (open) Sacrocolpopexy  Polyethylene  tetraphalate, 
Mersilene (Amid type III) 
 
Anti-incontinence : 
20/101 
Hysterectomy : NR 
 
4y (1-13) Efficacy 
Safety  
Higgs 2005b[46] 148 58 (10) 24/123 NR Abdominal (open) Sacrocolpopexy  Combined mesh, 
polyproglactine and prolene 
1 :1, Vypro; fascia lata; 
polypropylene, Prolene;  
polyethylene tetraphalate, 
Mersilene. 
 
Anti-incontinence : 
76/148 
Hysterectomy : 25/148 
45m (15) Efficacy 
Safety  
Lindeque 
2002[51] 
262 28-79 4/258 8/254 Abdominal (open) Sacrocolpopexy  18 dura mater strips, then 
changed to 
polytetrafluoroethylene, Gore-
Tex (Amid type II) 
 
Anti-incontinence: 
106/262 
Hysterectomy: NR 
All >=16m Efficacy 
Safety  
 
Snyder 1991[57] 147 62 (30-83) 3/144 NR Abdominal (open) Sacrocolpopexy Dacron graft (NR details); 
polytetrafluoroethylene, Gore-
Tex (Amid type II), and other 
type of mesh (NR) 
 
NR 43m (1m-17y) Efficacy 
Safety 
 
Timmons 
1992[59] 
163 58 (19-81) 163/3 NR Abdominal (open) Sacrocolpopexy  Fascial lata (NR trade name); 
polyethylene  tetraphalate, 
Mersilene (Amid type III) 
NR 33m (9m-18y) Safety  
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Appendix 2  Sacrocolpoperineopexy: summary of patient characteristics and surgical procedures  
 
ID N Age, y Uterine/
vault 
Primary/ 
secondary  
Intervention route Technique  Mesh/graft Concomitant procedure Follow up (mean) Outcomes  
Non-randomised comparative studies 
Visco 2001 
[31] 
A, 155 
B, 88 
C, 25 
D, 5 
A+B+C+D, 61 
(31-84) 
NR NR A, abdominal 
B, abdominal 
C, vaginal+ abdominal 
D, vaginal+ abdominal 
A, sacrocolpopexy 
B, sacrocolpoperineopexy  
C, sacrocolpoperineopexy 
D, sacrocolpoperineopexy 
with mesh placed to vaginal 
field 
 
A, polyethylene tetraphalate, 
Mersilene (Amid type III) or 
Gore-Tex (Amid type II) 
B, C, D, same as above 
Anti-incontinence: 
NR 
Hysterectomy: 
A+B+C+D: 45/273 
A, 7m (1-87) 
B, 5m (1-45) 
C, 6m (1-28) 
D, 7m (2-11) 
Safety  
Case series           
Su 
2007[40,58] 
169 62 (10) 5/164 NR Abdominal + vaginal Sacrocolpoperineopexy  Porcine dermis, Pelvicol; 
cadaveric fascia, Tutoplast; 
polypropylene, Gynemesh, 
Prolite, or Prolene (all Amid 
type I) 
Anti-incontinence: 155/169 
Hysterectomy: 11/169 
14m (1.5-24) Efficacy 
Safety  
 
NR: not reported 
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Appendix 3  Infracoccygeal sacropexy: summary of patient characteristics and surgical procedures 
ID N Age, y Uterine/ 
vault 
Primary/ 
secondary 
Intervention 
route 
Technique  Mesh/graft Anti-incontinence 
procedures 
Follow up Outcomes  
UTERINE           
Non-randomised comparative studies 
Neuman 2007[27] A, 44 
B, 35 
A, 64 (13) 
B, 51 (10) 
A, 44/0 
B, 35/0 
NR A, vaginal 
B, vaginal 
A, hysterectomy + infracoccygeal 
sacropexy 
B, infracoccygeal sacropexy with 
uterus preservation 
NR Anti-incontinence: 
A, 9/44; B, 6/35 
Hysterectomy: 
A, 44/44; B, 0/35 
30m (12-44) Efficacy 
Safety  
Case series (n<100)          
Sivaslioglu 2005[56]  10 60 (7) 10/0 NR Vaginal  Infracoccygeal sacropexy (presume 
uterus was preserved, as mean 
operation time was only 45min.) 
NR NR 16m (6) Efficacy 
Safety  
VAULT           
RCT (abs.)           
Meschia 2005[14] A, 30 
B, 30 
NR A, 0/30 
B, 0/30 
NR A, vaginal 
B, vaginal 
A, infracoccygeal sacropexy 
B, sacrospinous fixation 
A, NR 
B, no mesh 
NR 24m Safety  
Case series (n<100)          
Farnsworth 2002[41] 93 65 (36-77) 0/93 NR Vaginal  Infracoccygeal sacropexy 
 
Polypropylene tape (IVS Tunneller) 
 
NR 12m (2-24) Efficacy 
Safety  
Foote 2007[43] 
 
52 64 0/52 NR Vaginal  Infracoccygeal sacropexy Multifilament polypropylene (NR trade 
name) 
 
5/52 20wk Safety  
Ghanbari 2006[44] 
 
15 67 (50-
81)00 
0/15 NR Vaginal Infracoccygeal sacropexy Polypropylene tape (IVS Tunneller) 
 
NR NR Safety 
Petros 2001[53] 75 54 (40-74) 0/75 NR Vaginal Infracoccygeal sacropexy 
 
Nylon tape (NR trade name) NR 1-4.5y Efficacy 
Safety  
Sivaslioglu 2005[56] 
 
20 60 (7) 0/20 NR Vaginal  Infracoccygeal sacropexy NR NR 16m (6) Efficacy 
Safety  
UTERINE AND/OR VAULT         
RCT (abs.)           
De Tayrac 2006[15] A, 21 
B, 20 
NR NR NR A, vaginal 
B, vaginal 
A, infracoccygeal sacropexy 
B, unilateral sacrospinous suspension 
A, Tyco Healthcare 
B, no mesh 
Hysterectomy was 
performed as needed 
A, 11m (1.5-34) 
B, 16m (1.5-32) 
Efficacy 
Safety  
Case series (n ≥100)           
Hefni 2007[45] 127 59 (9) 83/44 NR Vaginal  Infracoccygeal sacropexy Multifilament polypropylene tape, IVS 
Tunneller 
 
Anti-incontinence : 
8/127 
Hysterectomy : 22/127 
14m (2-26) Efficacy 
Safety  
Vardy 2007[60] 286 
(53 for 
efficacy) 
61 (14) NR NR Vaginal  Infracoccygeal sacropexy Multifilament polypropylene tape, IVS 
Tunneller device (approved by FDA) 
Anti-incontinence: 
122/186 
Hysterectomy : NR 
1y Efficacy 
Safety  
Case series (n <100)           
Jordaan 2006[48] 8 NR NR NR Vaginal  Infracoccygeal sacropexy Absorbable and non-absorbable 
combined mesh, polyproglactine and 
prolene 1 :1, Vypro 
 
NR 13m  Efficacy  
Oliver 2006[52] 14 73 (18) 7/7 NR Vaginal  Modified infracoccygeal sacropexy 
with uterine preservation 
 
Polypropylene tape, IVS Tunneller Anti-incontinence: NR 
Hysterectomy: 3/7 
Efficacy: 6w 
Safety: 5m (2-11) 
Safety  
 42 
ID N Age, y Uterine/ 
vault 
Primary/ 
secondary 
Intervention 
route 
Technique  Mesh/graft Anti-incontinence 
procedures 
Follow up Outcomes  
Petros 2005[54] 67 65 (35-87) 23/40 NR Vaginal  Tissue Fixation System posterior 
sling (a direct evolution of the 
infracoccygeal sacropexy) 
Polypropylene, Tissue Fixation System 
device, approved by the Australian and 
European Government regulatory 
bodies 
 
NR 9m (3-15) Safety  
Sentihes 2007[55] 44 66 (50-84) 24/20 NR Vaginal  Non-absorbable hammock placement 
using anterior trans-obturator and 
posterior infracoccygeal extensions 
Polyester, Parietex, then changed to 
multifilament polypropylene, Surgipro, 
then low-weight monofilament 
polypropylene, Ugytex 
Anti-incontinence: 
0/44 
Hysterectomy: 24/44 
29m (9-47) Efficacy 
Safety  
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Appendix 4  Uterine suspension sling: summary of patient characteristics and surgical procedures (uterine prolapse only)   
 
ID N Age, y Uterine/
vault 
Primary/ 
secondary  
Intervention route Technique  Mesh/graft Concomitant procedure Follow up (mean) Outcomes  
RCT           
Roovers 
2004[12] 
A, 41 
B, 41 
A, 58 (9) 
B, 56 (11) 
A, 41/0 
B, 41/0 
NR A, abdominal 
B, vaginal 
A, sacrohysteropexy 
B, hysterectomy + anterior 
and/or posterior colporrhaphy 
A, polypropylene, Gore-Tex 
(Amid type II) 
B, no mesh 
Anti-incontinence: 
A, 16/41; B,11/41 
Hysterectomy: 
A, 2/41 (B was performed); B, 
41/41  
1y Efficacy 
Safety 
 
Non-randomised comparative studies 
Costantini 
2005[19] 
A, 36 
B, 39 
A, 61 (12) 
B, 62 (8) 
A, 36/0 
B, 39/0 
NR A, abdominal 
B, abdominal 
A, sacrohysteropexy 
B, hysterectomy + sacropexy 
A, polypropylene, Marlex 
(Amid type I) 
B, same as A 
Anti-incontinence: 
A, 28/36; B, 30/39 
Hysterectomy: 
A, 0/36; B, 39/39 
51m (12-115) Efficacy 
Safety  
Case series (n <100)          
Banu 1997[33] 19 17-27 19/0 NR Abdominal (open) Sacrohysteropexy  Polyester, Mersilene (Amid 
type III) 
Hysterectomy: 0/19 3-5y Efficacy  
Safety 
 
Barranger 
2003[34] 
30 35.7 (29-43) 30/0 29/1 Abdominal (open) Sacrohysteropexy  Polyester, Mersuture Anti-incontinence: 30/30 
Hysterectomy: 0/30 
Efficacy: 44.5m (2-
156); 
Safety: 94.6m (8-
160) 
 
Efficacy 
Safety  
Leron 2001[50] 13 39 (27-60) 13/0 NR Abdominal (open) Sacrohysteropexy  Non-absorbable synthetic 
mesh, Teflon 
Anti-incontinence: 4/13 
Hysterectomy: 0/13 
 
16m (4-49) Efficacy 
Safety  
Joshi 1993[49] 20 27.5 (17-32) 20/0 19/1 Abdominal (open) Uterine suspension sling (uterus 
is suspended to the pectineal 
ligaments) 
Non-absorbable synthetic 
mesh, Mersilene (Amid type 
III) 
Anti-incontinence: 5/20 
Hysterectomy: 0/19 
6-30m Efficacy 
Safety  
 
NR: not reported 
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Figure S1 Summary of quality assessment of the RCTs (full text, n=5) 
0% 20% 40% 60% 80% 100%
Q13. Experienced practitioner
Q12. ITT or no w ithdraw s/drop-outs after recruitment
Q11. Withdraw als/drop-outs unlikely to cause bias 
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Q7. Mean follow -up ≥1y
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Figure S2 Summary of quality assessment of the non-randomised comparative studies 
(n=17) 
0% 20% 40% 60% 80% 100%
Q18. Analyses adjusted for confounding factors
Q17. Important prognostic factors identif ied
Q16. Follow -up similar betw een groups
Q15. Withdraw als/drop-outs unlikely to cause bias 
Q14. Information provided on non-respondents/drop-outs
Q13. Mean follow -up ≥1y
Q12. Outcome assessor blinded
Q11.Objective outcome measures used
Q10. Important outcomes considered
Q9. Appropriate treatment place
Q8. Experienced practitioner
Q7. Intervention clearly defined
Q6. Similar baseline characteristics betw een groups
Q5. Data collection w as undertaken prospectively
Q4. Selection of patients w as consecutive
Q3. Similar participant baseline characteristics
Q2. Participant inclusion/exclusion criteria described
Q1. Participant representativeness
Yes
No
Unclear
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Figure S3 Summary of quality assessment of the case series (n=29) 
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